{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:49:19Z","timestamp":1792658959389,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1160408"],"award-info":[{"award-number":["OPP1160408"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.xphs.2021.07.018","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T02:52:21Z","timestamp":1628391141000},"page":"3670-3677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Amorphous Drug\u2013Polymer Salt with High Stability under Tropical Conditions and Fast Dissolution: The Challenging Case of Lumefantrine-PAA"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7657-4997","authenticated-orcid":false,"given":"Xin","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soojin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4416-3907","authenticated-orcid":false,"given":"Yue","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3383-8139","authenticated-orcid":false,"given":"Zhenxuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junguang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2021.07.018_bib0001","series-title":"World Malaria Report","year":"2019"},{"issue":"6","key":"10.1016\/j.xphs.2021.07.018_bib0002","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00044011-199918060-00006","article-title":"Clinical pharmacokinetics of artemether and lumefantrine (Riamet\u00ae)","volume":"18","author":"Lef\u00e8vre","year":"1999","journal-title":"Clin Drug Investig"},{"issue":"2","key":"10.1016\/j.xphs.2021.07.018_bib0003","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00003088-199937020-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine","volume":"37","author":"White","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.xphs.2021.07.018_bib0004","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1046\/j.1365-3156.2003.01186.x","article-title":"Artemether-lumefantrine for uncomplicated malaria: a systematic review","volume":"9","author":"Omari","year":"2004","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.xphs.2021.07.018_bib0005","series-title":"Guidelines for the Treatment of Malaria","year":"2015"},{"key":"10.1016\/j.xphs.2021.07.018_bib0006","series-title":"Novartis Pharma AG","article-title":"Annual report","year":"2015"},{"issue":"2","key":"10.1016\/j.xphs.2021.07.018_bib0007","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","article-title":"Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system","volume":"58","author":"Lindenberg","year":"2004","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2021.07.018_bib0008","first-page":"180","article-title":"Development, characterization and evaluation of solid dispersion of Artemether and Lumefantrine solvent evaporation method using hydrophilic polymers","volume":"6(2)","author":"Anna","year":"2014","journal-title":"Int. J Pharm Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2021.07.018_bib0009","first-page":"434","article-title":"The effect of food consumption on lumefantrine bioavailability in African children receiving artemether\u2013lumefantrine crushed or dispersible tablets (Coartem\u00ae) for acute uncomplicated Plasmodium falciparum malaria","volume":"15","author":"Borrmann","year":"2010","journal-title":"Trop Med Int Health"},{"issue":"2","key":"10.1016\/j.xphs.2021.07.018_bib0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-3156.2006.01784.x","article-title":"How much fat is necessary to optimize lumefantrine oral bioavailability?","volume":"12","author":"Ashley","year":"2007","journal-title":"Trop Med Int Health"},{"issue":"1","key":"10.1016\/j.xphs.2021.07.018_bib0011","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0169-409X(01)00098-9","article-title":"Amorphous pharmaceutical solids: preparation, characterization and stabilization","volume":"48","author":"Yu","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"10.1016\/j.xphs.2021.07.018_bib0012","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.xphs.2015.10.008","article-title":"Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs","volume":"105","author":"Baghel","year":"2016","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2021.07.018_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00868-17","article-title":"Bioavailability of lumefantrine is significantly enhanced with a novel formulation approach, an outcome from a randomized, open-label pharmacokinetic study in healthy volunteers","volume":"61","author":"Jain","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2021.07.018_bib0014","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/CBO9780511552083.002","article-title":"Water as a plasticizer: physico-chemical aspects of low-moisture polymeric systems","volume":"3","author":"Levine","year":"1988","journal-title":"Water Sci Rev"},{"issue":"3","key":"10.1016\/j.xphs.2021.07.018_bib0015","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1021\/js9602711","article-title":"Effects of sorbed water on the crystallization of indomethacin from the amorphous state","volume":"86","author":"Andronis","year":"1997","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2021.07.018_bib0016","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijpharm.2016.06.126","article-title":"Acid-base interactions in amorphous solid dispersions of lumefantrine prepared by spray-drying and hot-melt extrusion using X-ray photoelectron spectroscopy","volume":"514","author":"Song","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2021.07.018_bib0017","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1039\/c2ce26055g","article-title":"Acid-base crystalline complexes and the pKa rule","volume":"14","author":"Cruz-Cabeza","year":"2012","journal-title":"CrystEngComm"},{"key":"10.1016\/j.xphs.2021.07.018_bib0018","doi-asserted-by":"crossref","first-page":"8199","DOI":"10.1021\/ja0541332","article-title":"Solid-state acid\u2212base interactions in complexes of heterocyclic bases with dicarboxylic acids: crystallography, hydrogen bond analysis, and 15N NMR spectroscopy","volume":"128","author":"Li","year":"2006","journal-title":"J Am Chem Soc"},{"issue":"6","key":"10.1016\/j.xphs.2021.07.018_bib0019","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1002\/jps.21584","article-title":"Improved physical stability of amorphous state through acid base interactions","volume":"98","author":"Telang","year":"2009","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2021.07.018_bib0020","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1023\/A:1018985110956","article-title":"Solid-state characteristics of amorphous sodium indomethacin relative to its free acid","volume":"16","author":"Tong","year":"1999","journal-title":"Pharm Res"},{"issue":"12","key":"10.1016\/j.xphs.2021.07.018_bib0021","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/jps.1150","article-title":"A study of amorphous molecular dispersions of indomethacin and its sodium salt","volume":"90","author":"Tong","year":"2001","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2021.07.018_bib0022","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1021\/acs.molpharmaceut.5b00333","article-title":"Role of the strength of drug\u2013polymer interactions on the molecular mobility and crystallization inhibition in ketoconazole solid dispersions","volume":"12","author":"Mistry","year":"2015","journal-title":"Mol Pharm"},{"issue":"39","key":"10.1016\/j.xphs.2021.07.018_bib0023","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1039\/C9CC02021G","article-title":"A supramolecular synthon approach to design amorphous solid dispersions with exceptional physical stability","volume":"55","author":"Duggirala","year":"2019","journal-title":"Chem Commun"},{"key":"10.1016\/j.xphs.2021.07.018_bib0024","series-title":"Pharmaceutical Salts: Properties, Selection and Use","author":"Stahl","year":"2002"},{"issue":"9","key":"10.1016\/j.xphs.2021.07.018_bib0025","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.1021\/la070050i","article-title":"Inhibiting surface crystallization of amorphous indomethacin by nanocoating","volume":"23","author":"Wu","year":"2007","journal-title":"Langmuir"},{"issue":"3","key":"10.1016\/j.xphs.2021.07.018_bib0026","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1021\/acs.molpharmaceut.8b01237","article-title":"Polymer nanocoating of amorphous drugs for improving stability, dissolution, powder flow, and tabletability: the case of chitosan-coated indomethacin","volume":"16","author":"Li","year":"2019","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2021.07.018_bib0027","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11095-019-2584-9","article-title":"Improving stability and dissolution of amorphous clofazimine by polymer nano-coating","volume":"36","author":"Gui","year":"2019","journal-title":"Pharm. Res"},{"issue":"7","key":"10.1016\/j.xphs.2021.07.018_bib0028","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.xphs.2019.02.018","article-title":"Inhibiting surface crystallization and improving dissolution of amorphous loratadine by dextran sulfate nanocoating","volume":"108","author":"Zeng","year":"2019","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2021.07.018_bib0029","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1021\/acs.molpharmaceut.5b00708","article-title":"Acid\u2013base interactions of polystyrene sulfonic acid in amorphous solid dispersions using a combined UV\/FTIR\/XPS\/ssNMR study","volume":"13","author":"Song","year":"2016","journal-title":"Mol Pharm"},{"issue":"11","key":"10.1016\/j.xphs.2021.07.018_bib0030","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1021\/acs.molpharmaceut.6b00740","article-title":"Solid-state spectroscopic investigation of molecular interactions between clofazimine and hypromellose phthalate in amorphous solid dispersions","volume":"13","author":"Nie","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2021.07.018_bib0031","article-title":"Physical stability and release properties of lumefantrine amorphous solid dispersion granules prepared by a simple solvent evaporation approach","volume":"2","author":"Trasi","year":"2020","journal-title":"Int J Pharm X"},{"issue":"3","key":"10.1016\/j.xphs.2021.07.018_bib0032","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1021\/acs.molpharmaceut.0c01180","article-title":"Amorphous drug\u2013polymer salt with high stability under tropical conditions and fast dissolution: the case of clofazimine and poly (acrylic acid)","volume":"18","author":"Gui","year":"2021","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2021.07.018_bib0033","first-page":"95","article-title":"Dissolution rate enhancement and physicochemical characterization of artemether and lumefantrine solid dispersions","volume":"4","author":"Fule","year":"2012","journal-title":"Int J Drug Deliv"},{"issue":"14","key":"10.1016\/j.xphs.2021.07.018_bib0034","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1021\/la027012d","article-title":"In situ FTIR-ATR examination of poly (acrylic acid) adsorbed onto hematite at low pH","volume":"19","author":"Kirwan","year":"2003","journal-title":"Langmuir"},{"key":"10.1016\/j.xphs.2021.07.018_bib0035","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1021\/ci025515j","article-title":"Application of associative neural networks for prediction of lipophilicity in ALOGPS 2.1 program","volume":"42","author":"Tetko","year":"2002","journal-title":"J Chem Inf Comput Sci"},{"issue":"8","key":"10.1016\/j.xphs.2021.07.018_bib0036","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1002\/jps.22579","article-title":"Dissolution and precipitation behavior of amorphous solid dispersions","volume":"100","author":"Alonzo","year":"2011","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2021.07.018_bib0037","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1021\/acs.molpharmaceut.5b00652","article-title":"Dissolution of danazol amorphous solid dispersions: supersaturation and phase behavior as a function of drug loading and polymer type","volume":"13","author":"Jackson","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2021.07.018_bib0038","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejpb.2018.09.022","article-title":"Jejunal absorption of aprepitant from nanosuspensions: role of particle size, prandial state and mucus layer","volume":"132","author":"Roos","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"10.1016\/j.xphs.2021.07.018_bib0039","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11095-008-9750-9","article-title":"Colloidal structures in media simulating intestinal fed state conditions with and without lipolysis products","volume":"26","author":"Fatouros","year":"2009","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2021.07.018_bib0040","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1021\/mp5005788","article-title":"Compression-induced crystallization of amorphous indomethacin in tablets: characterization of spatial heterogeneity by two-dimensional X-ray diffractometry","volume":"12","author":"Thakral","year":"2015","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2021.07.018_bib0041","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1021\/acs.molpharmaceut.6b00202","article-title":"Exploiting the phenomenon of liquid\u2013liquid phase separation for enhanced and sustained membrane transport of a poorly water-soluble drug","volume":"13","author":"Indulkar","year":"2016","journal-title":"Mol Pharm"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921004020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921004020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:35:19Z","timestamp":1758360919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354921004020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0022354921004020"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2021.07.018","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amorphous Drug\u2013Polymer Salt with High Stability under Tropical Conditions and Fast Dissolution: The Challenging Case of Lumefantrine-PAA","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2021.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}